KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Common Equity (2016 - 2026)

Gsk has reported Common Equity over the past 18 years, most recently at $23.5 billion for Q1 2026.

  • For Q1 2026, Common Equity rose 36.58% year-over-year to $23.5 billion; the TTM value through Mar 2026 reached $23.5 billion, up 36.58%, while the annual FY2025 figure was $21.2 billion, 20.96% up from the prior year.
  • Common Equity for Q1 2026 was $23.5 billion at Gsk, up from $21.2 billion in the prior quarter.
  • Over five years, Common Equity peaked at $36.0 billion in Q1 2022 and troughed at $10.3 billion in Q3 2022.
  • A 5-year average of $18.8 billion and a median of $17.4 billion in 2024 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 65.74% in 2022 and later surged 55.61% in 2023.
  • Year by year, Common Equity stood at $12.4 billion in 2022, then soared by 33.26% to $16.6 billion in 2023, then grew by 5.92% to $17.5 billion in 2024, then grew by 20.96% to $21.2 billion in 2025, then grew by 10.67% to $23.5 billion in 2026.
  • Business Quant data shows Common Equity for GSK at $23.5 billion in Q1 2026, $21.2 billion in Q4 2025, and $21.3 billion in Q3 2025.